SG/PUT/BRISTOL-MYERS SQUIBB/55/0.1/21.03.25

SG/PUT/BRISTOL-MYERS SQUIBB/55/0.1/21.03.25 Stock

DE000SU7K520

Real-time Boerse Frankfurt Warrants 01:06:45 2024-06-19 pm EDT
1.37 ^EUR	-0.72%

Current month	+1.47%
1 month	+27.78%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/PUT/BRISTOL-MYERS SQUIBB/55/0.1/21.03.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers: ex-CEO of Agilent joins Board of Directors	01:11am	CF
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors	Jun. 18	BU
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	Jun. 18	CI
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	Jun. 18	MT

More news

Quotes 5-day view

Date	Price	Change
24-06-19	1.37	-0.72%
24-06-18	1.38	+1.47%
24-06-17	1.36	+2.26%
24-06-14	1.33	+1.53%
24-06-13	1.31	+7.38%

Real-time Boerse Frankfurt Warrants

Last update June 19, 2024 at 01:06 pm EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SU7K52
ISIN	DE000SU7K520
Date issued	2024-01-29
Strike	55 $
Maturity	2025-03-21 (275 Days)
Parity	10 : 1
Emission price	0.77 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.42 €
Lowest since issue	0.49 €
Spread	0.02 €
Spread %	1.44%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company